Zacks Rating on Insulet Corporation (PODD)

Insulet Corporation (PODD) : The consensus on Insulet Corporation (PODD) based on 14 analyst recommendation on the company stock is 1.79, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 8 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Insulet Corporation (PODD) : The most positive equity analysts on Insulet Corporation (PODD) expects the shares to touch $52, whereas, the least positive believes that the stock will trade at $38 in the short term. The company is covered by 11 Wall Street Brokerage Firms. The average price target for shares are $42.84 with an expected fluctuation of $5.02 from the mean.


Insulet Corporation has dropped 2.08% in the last five trading days, however, the shares have posted positive gains of 27.28% in the last 4 weeks. Insulet Corporation is up 42.79% in the last 3-month period. Year-to-Date the stock performance stands at 14.65%. Insulet Corporation (NASDAQ:PODD): On Tuesdays trading session , Opening price of the stock was $43.94 with an intraday high of $43.94. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $43.21. However, the stock managed to close at $43.35, a loss of 0.60% for the day. On the previous day, the stock had closed at $43.61. The total traded volume of the day was 286,357 shares.

Insulet Corporation is a medical device company engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin infusion system for people with insulin-dependent diabetes. The Companys principal offices are located in Billerica, Massachusetts. Features of the OmniPod System include two-part design, no tubing, and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod, a small, lightweight, disposable insulin infusion device worn beneath clothing; and the PDM, a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated, hands-free cannula insertion system.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.